Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Transdermal Patch Uses Electricity to Deliver Iron to Patients with Iron Deficiency

April 12, 2019 By Fe3 Medical

 Fe3 Medical, the creators of a transdermal patch for the treatment of iron deficiency anemia, announced the results from its first human study of the Fe3 proprietary biphasic iontophoretic transdermal technology. Fe3’s technology is designed as an alternative therapy for the millions of patients who suffer from debilitating effects of iron deficiency anemia, but cannot tolerate the current oral therapies available. The human study focused on the safety and tolerability of Fe3’s proprietary iontophoretic transdermal technology designed to bypass ionic resistance build up in the skin. The human study follows a series of successful preclinical studies demonstrating the safe delivery of iron through the skin.

For the millions of patients with gastrointestinal diseases such as celiac disease, inflammatory bowel disease or Crohn’s disease, as well as those with peptic ulcers, gastric bypass operations or heavy menstrual bleeding, iron deficiency anemia is a serious condition that can result in fatigue, poor cognition and defects in motor function. For the majority of these patients, oral iron is their only therapy option yet more than 45 percent of these patients cannot tolerate the effects of the oral therapy due to side effects such as nausea, constipation and diarrhea. The Fe3 iontophoretic transdermal patch together with a generic iron compound may provide an alternative therapy for patients who cannot use oral therapy by delivering therapeutic levels of iron without gastrointestinal side effects. In addition, the Fe3 approach significantly reduces adverse effects of traditional transdermal drug delivery such as burns and skin discoloration. 

The human study was conducted at a Clinical Research Organization (CRO) in Texas, under Investigational Review Board (IRB) approval. The company conducted safety and tolerability studies, evaluating iron transport with Fe3’s proprietary transdermal platform in forty healthy volunteers.

After mild skin preparation, the Fe3 patch was applied to the thigh of the subject. The patch was programmed for a short hydration interval followed by approximately five hours of active therapy. The study demonstrated successful iron transport, with a rapid rise in serum iron levels during the first four hours and a decline and return to baseline within 24 hours. Dose-dependent increases in iron transport, consistent with expected transport rates, were also observed. No adverse effects were experienced by the subjects, including no scarring or long term staining of the skin. Mild edema or erythema resolved within three days.

“We are focused on bringing a new therapy option to the millions of patients suffering from iron deficiency anemia on a worldwide basis,” said Mark Sieczkarek, CEO of Fe3 Medical. “Our first human study, along with our extensive preclinical studies, give us the confidence that our transdermal patch technology can effectively and safely deliver therapeutic levels of iron. We are now preparing for the next exciting phase for Fe3 and an upcoming clinical trial.” 

The Fe3 technology is based on the company’s proprietary iontophoresis system. The concept for the Fe3 patch technology was developed and refined at InCube Labs, a life science research and development lab founded by Mir Imran, a prolific inventor and entrepreneur and Chairman of the Board of Fe3. The first human studies followed a series of preclinical tests in swine with the clinical device. A porcine model was selected due to its wide acceptance as a model for human skin. Similar parameters were used in preclinical testing including testing for levels of iron and device safety. 

“The transdermal technology platform that Fe3 is based on is capable of delivering a broad range of molecules in a highly controlled fashion, which makes it a great platform for iron, as well as other drugs such as Diclofenac for pain and inflammation and Sumatriptan for migraines,” Mir Imran, Chairman and CEO of InCube Labs, said.

The company has 47 issued patents, as well as 80+ applications filed in the US and major foreign jurisdictions.

Related Articles Read More >

A woman wearing a hearing aid
Why filter bank design is critical for effective hearing aids
Northwestern University dissolvable pacemaker
This smart, dissolving pacemaker communicates with sensors on the body for remote patient monitoring
Outcome-Based Technologies' Excyabir CryoKnee
DJO’s Enovis buys orthopedic bracing assets of Outcome-Based Technologies
An array of Varta microbatteries
Varta presents microbattery product portfolio at Computex 2022

DeviceTalks Weekly.

June 24, 2022
How innovative design, commercial strategy is building Cala Trio’s bioelectronic medicine market
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech